Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 15/20 | 0.61 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758228 | 1.00 | MAOB (0.61) | MAOBAOC3FKBP1ANPC1PKM | |
| SCHEMBL3758225 | 1.00 | MAOB (0.61) | MAOBAOC3FKBP1ANPC1PKM | |
| Hydrochloric Acid SCHEMBL2947233 | 0.99 | MAOB (0.59) | MAOBAOC3FKBP1ANPC1PKM | |
| Hydrochloric Acid SCHEMBL3749853 | 0.99 | MAOB (0.59) | MAOBAOC3FKBP1ANPC1PKM | |
| Hydrochloric Acid SCHEMBL2947230 | 0.99 | MAOB (0.59) | MAOBAOC3FKBP1ANPC1PKM | |
| SCHEMBL2947768 | 0.76 | AOC3 (0.47) | MAOBAOC3FKBP1ANPC1RAB9A | |
| SCHEMBL2947775 | 0.76 | AOC3 (0.47) | MAOBAOC3FKBP1ANPC1RAB9A | |
| SCHEMBL2947773 | 0.76 | AOC3 (0.47) | MAOBAOC3FKBP1ANPC1RAB9A | |
| SCHEMBL3756755 | 0.76 | AOC3 (1.00) | MAOBAOC3 | |
| SCHEMBL3756753 | 0.76 | AOC3 (1.00) | MAOBAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | claimed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | claimed |
| EP-2222160-B1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8426587-B2 | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor | PHARMAXIS LTD. (AU) | 2013-04-23 | — | — | US | disclosed |
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | PHARMAXIS LTD. (AU) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298330-A1 | HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR | VAPA, SLC6A11, VAPB | MAOB 295/4885AOC3 30/4885FKBP1A 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.